Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamaoncol.2025.1337 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risks for adverse events by sex and age after prescription opioid dose reduction.
Am J Prev Med
September 2025
Kaiser Permanente Northern California, Division of Research, Center for Addiction and Mental Health Research, Pleasanton, CA, United States.
Introduction: Prescription opioid dose reductions can raise the risk of adverse events for patients on long-term opioid therapy for non-cancer pain. Evidence on whether risks differ by age or sex is needed to support tailored clinical decision-making.
Methods: In 2024, a secondary analysis of an observational cohort study was conducted across 8 U.
Haloperidol potentates the antinociceptive effect of buprenorphine and tramadol in rats.
Behav Pharmacol
October 2025
Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico.
This study aimed to evaluate the pharmacological effects of haloperidol on the antinociceptive effects of buprenorphine and tramadol in rats. Dose-response curves were constructed for the individual administration of haloperidol, buprenorphine, and tramadol in rats subjected to the formalin (1%) test. All the compounds demonstrated dose-dependent antinociceptive effects when administered individually.
View Article and Find Full Text PDFA Stepwise Approach to Transitioning from Methadone to Buprenorphine for Cancer-Related Pain in an Outpatient Setting: A Novel Opioid Rotation Without Clinically Evident Withdrawal Symptoms.
J Pain Palliat Care Pharmacother
September 2025
Department of Palliative Medicine, University of Illinois College of Medicine Peoria, Peoria, Illinois, USA.
This case report details a successful transition of a patient with cancer-related pain from long-term methadone therapy to sublingual buprenorphine using a micro-induction protocol in an outpatient setting. The transition involved initiating low-dose transdermal buprenorphine while gradually tapering methadone, followed by the introduction of sublingual buprenorphine. This approach resulted in a smooth conversion without clinically evident withdrawal symptoms and led to improved pain control, reduced adverse effects, and enhanced functional status.
View Article and Find Full Text PDFBackground And Aim: Urine drug testing is often utilized alongside opioid agonist treatment to assess client progress by validating self-reported substance use, monitoring for diversion and supporting clinical decisions for take-home dosing. However, there is a paucity of evidence to support the practice of urine drug testing. We aimed to determine the association of alternative urine drug testing frequencies with opioid agonist treatment discontinuation, compared with no monitoring, among individuals receiving methadone or buprenorphine/naloxone treatment.
View Article and Find Full Text PDFNurse prescribing right: a bibliometric analysis.
Front Med (Lausanne)
August 2025
School of Nursing, Wannan Medical College, Wuhu, Anhui, China.
Background: The concept of nurse prescribing rights is undergoing rapid evolution, and there is increasing interest in academic circles regarding research on this topic.
Objective: This study aims to conduct a comprehensive bibliometric analysis of nurses' prescribing rights to understand the research background, emerging trends, and relevant academic impacts in this field, so as to provide valuable insights for the formulation of health policies and the promotion of more equitable and efficient healthcare services.
Methods: We conducted a bibliometric analysis of the articles on nurses' prescribing rights from the establishment of the database until 6 December 2023.